Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome

Nephrotic Syndrome Clinical Trial

Official title: Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial

Status Terminated

Clinical Trial Summary

Double-blind, two-parallel-arm, placebo-controlled randomized clinical trial testing the superiority of Ofatumumab versus placebo in the treatment of children with DR-INS. Participants will be stratified according to eGFR at enrollment.

Eligible participants will enter a 3-months run-in period, during which instructions on urine collection and dipstick readings will be carefully reviewed, compliance assessed and any immunosuppressive therapies withdrawn according to the following schemes:

• prednisone will be tapered off by 0.3 mg/kg per week until complete withdrawal;

• calcineurin inhibitors and mofetile mycophenolate will be decreased by 50% and withdrawn after 2 additional weeks In order to minimize the risk of complications of uncontrolled INS a treatment with ACE-inhibitor at 6 mg/m2 will be maintained or started in all patients.

After run-in period, children will be randomized to the intervention arm (Ofatumumab) or comparator arm (placebo). Randomization will be stratified by eGFR at randomization: ≥90 and <90 ml/min/1.73 m2.

All patients will be followed up to 12 months and they will leave the study at time of relapse.

Relapse will be defined as uPCR ≥2000 mg/g (≥200 mg/mmol) or ≥ 3+ protein on urine dipstick for 3 consecutive days.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Nephrosis
• Nephrotic Syndrome
• Syndrome

• NCT number: NCT02394106
• Study type: Interventional
• Source: Istituto Giannina Gaslini
• Status: Terminated
• Phase: Phase 2
• Start date: July 2015
• Completion date: June 2019